Pablo Barreiro

Summary

Publications

  1. doi request reprint Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy
    Pablo Barreiro
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Infect Dis 203:1629-36. 2011
  2. ncbi request reprint Is natural conception a valid option for HIV-serodiscordant couples?
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Hum Reprod 22:2353-8. 2007
  3. ncbi request reprint Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J HIV Ther 14:13-8. 2009
  4. ncbi request reprint Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:429-37. 2008
  5. ncbi request reprint [Hepatitis B in patients with HIV infection]
    Pablo Barreiro
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:71-9. 2008
  6. doi request reprint Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV
    Jose Medrano
    Department of Infectious Diseases, Hospital Carlos III, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
    Clin Infect Dis 51:1209-16. 2010
  7. ncbi request reprint Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    AIDS Res Hum Retroviruses 23:972-82. 2007
  8. ncbi request reprint Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Infect Disord Drug Targets 6:57-88. 2006
  9. doi request reprint Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection
    Judit Morello
    Laboratory of Pharmacology, Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 202:1185-91. 2010
  10. ncbi request reprint Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b
    Eugenia Vispo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:511-7. 2008

Detail Information

Publications105 found, 100 shown here

  1. doi request reprint Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy
    Pablo Barreiro
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Infect Dis 203:1629-36. 2011
    ....
  2. ncbi request reprint Is natural conception a valid option for HIV-serodiscordant couples?
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    Hum Reprod 22:2353-8. 2007
    ..The objective of this paper is to propose a protocol that may minimize risks in HIV-discordant couples that have opted for natural conception...
  3. ncbi request reprint Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J HIV Ther 14:13-8. 2009
    ..At this time, most experts agree that early introduction of anti-HBV active HAART is the best strategy for the treatment of chronic hepatitis B in HIV patients, and Truvada must be part of the triple regimen...
  4. ncbi request reprint Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:429-37. 2008
    ..There is little information about the influence of antiretroviral drugs on the antiviral activity of pegylated interferon (PEG-IFN) plus ribavirin (RBV) against hepatitis C virus (HCV)...
  5. ncbi request reprint [Hepatitis B in patients with HIV infection]
    Pablo Barreiro
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:71-9. 2008
    ..Patients with cirrhosis should undergo ultrasonography and alphafetoprotein determination every 6 months for the early detection of hepatocellular carcinoma...
  6. doi request reprint Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV
    Jose Medrano
    Department of Infectious Diseases, Hospital Carlos III, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
    Clin Infect Dis 51:1209-16. 2010
    ..Given that therapy is poorly tolerated and rates of response are lower in patients coinfected with HCV and human immunodeficiency virus (HIV), the recognition of predictors of response is a high priority in this population...
  7. ncbi request reprint Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    AIDS Res Hum Retroviruses 23:972-82. 2007
    ..The use of RBV 1000-1200 mg/day plus pegIFN is relatively safe and provides SVR in nearly half of coinfected patients, twice as high in HCV-2/3 than HCV-1/4...
  8. ncbi request reprint Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Infect Disord Drug Targets 6:57-88. 2006
    ..The relatively low efficacy of current anti-HCV medications and their low tolerability clearly indicated the need for new drugs with more potent and direct antiviral activity against HCV...
  9. doi request reprint Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection
    Judit Morello
    Laboratory of Pharmacology, Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 202:1185-91. 2010
    ....
  10. ncbi request reprint Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b
    Eugenia Vispo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 13:511-7. 2008
    ..Differences between PEG-IFN-alpha molecules could be more pronounced in HIV-coinfected individuals, in whom response to HCV treatment is impaired...
  11. doi request reprint Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS 22:2535-7. 2008
    ..A substantial proportion of patients under atazanavir-therapy experienced significant hyperbilirubinemia and jaundice following initiation of hepatitis-C therapy...
  12. ncbi request reprint Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 7:163-71. 2006
    ..Regimens based on ritonavir-boosted protease inhibitors (PI/r) are often used as rescue interventions. It is unclear whether significant differences exist between distinct PI/r...
  13. ncbi request reprint Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 61:200-5. 2008
    ..If proved, this strategy could be particularly attractive for the subset of patients with greater cardiovascular risk...
  14. ncbi request reprint [Role of tenofovir in HIV and hepatitis C virus coinfection]
    Paula Tuma
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 26:31-7. 2008
    ..Tenofovir is currently one of the safest nucleos(t)ide analogues, due to its low hepatotoxicity and its lack of negative interference on treatment of HCV infection...
  15. pmc Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C
    Judit Morello
    Laboratory of Pharmacology, Hospital Carlos III, 28029 Madrid, Spain
    Antimicrob Agents Chemother 54:1647-9. 2010
    ..5 microg/ml (4.5 [1.3 to 15.5]), baseline serum HCV RNA (2.5 [1.2 to 5.1]), and HCV genotype 1 or 4 (13.3 [2.6 to 66.7]). Monitoring of RBV C(trough) may permit early adjustment of RBV dosage to avoid HCV relapse...
  16. doi request reprint Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse
    Pablo Labarga
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    J Acquir Immune Defic Syndr 53:364-8. 2010
    ....
  17. ncbi request reprint Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir
    Teresa Garcia-Benayas
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:333-7. 2006
    ..These results add a further note of caution to the use of TDF and ddI in combination...
  18. ncbi request reprint Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 195:973-9. 2007
    ..Most antiretrovirals are metabolized in the liver, and lower dosing could be advisable in patients with severe liver insufficiency...
  19. ncbi request reprint Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 24:821-5. 2008
    ..Patients with complete viral suppression under ATV/r 300/100 mg qd may benefit from switching to ATV 400 mg qd guided by TDM, which may make it possible to minimize adverse events without compromising antiviral efficacy in most cases...
  20. ncbi request reprint Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients
    Luz Martin-Carbonero
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:1231-5. 2006
    ..The presence of TAMs precluded the selection of K65R in patients treated with TDF. Resistance pathways for TDF and thymidine analogues seem to be divergent and could be the basis to explore a synergism between these drugs...
  21. ncbi request reprint Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 21:583-8. 2007
    ..Information on the impact of therapy with pegylated interferon (pegIFN) plus ribavirin on mtDNA is scarce and conflicting results have been reported...
  22. doi request reprint Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial
    Eugenia Vispo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 11:197-204. 2010
    ..Raltegravir has demonstrated good antiviral activity and safety profile in twice-daily (bid) dosing. However, its long terminal elimination half-life might allow once-daily (qd) administration...
  23. ncbi request reprint Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Infect Dis 192:1245-8. 2005
    ..Coinfection with distinct HCV genotypes is unlikely in former IDUs coinfected with HIV and does not explain the lower efficacy of HCV therapy in this population...
  24. doi request reprint Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir
    Pablo Labarga
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    AIDS 23:689-96. 2009
    ..Kidney abnormalities are the main concern using the drug. As glomerular function is infrequently affected in patients treated with TDF, herein, we report the results of an extensive examination of tubular function...
  25. ncbi request reprint Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1
    Sonia Rodriguez Novoa
    Clinical Pharmacokinetic Unit, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 42:291-5. 2006
    ..Plasma levels of atazanavir were significantly higher in patients with genotype CC than in those with CT or TT, and bilirubin levels correlated with atazanavir concentrations...
  26. ncbi request reprint Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients
    Pablo Labarga
    Department of Infectious Diseases, Hospital Carlos III, Madrid 28029, Spain
    J Infect Dis 196:670-6. 2007
    ..It is unknown whether sustained HCV clearance after interferon (IFN)-based therapy might reduce this complication...
  27. ncbi request reprint Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:842-8. 2006
    ..Thus, HBV/HIV-coinfected patients might benefit from an earlier introduction of HAART...
  28. ncbi request reprint Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity
    Ivana Maida
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 7:246-50. 2006
    ..The extent and predictors of liver fibrosis were examined in a HIV/HBVcoinfected cohort with extensive exposure to anti-HBV active HAART...
  29. doi request reprint Differences in virological response to peginterferon-α plus ribavirin in HIV-positive patients coinfected with HCV subtypes 1a or 1b
    Norma I Rallon
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Acquir Immune Defic Syndr 60:117-23. 2012
    ..The impact of these variables is more pronounced in HIV/Hepatitis C virus (HCV)-coinfected individuals, in whom treatment response rates are lower...
  30. ncbi request reprint Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia
    Sonia Rodriguez-Novoa
    Pharmacokinetic and Pharmacogenetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS 21:41-6. 2007
    ..Polymorphisms at the uridin-glucoronosyl-transferase 1A1 (UGT1A1) and multidrug resistance 1 (MDR1) genes may influence, respectively, bilirubin and ATV plasma concentrations...
  31. doi request reprint Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain
    Clara Sánchez
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Liver Int 33:1357-62. 2013
    ..Outbreaks of acute hepatitis C in HIV-positive men who have sex with men (MSM) are being reported in large cities in western countries along with increasing rates of sexually transmitted diseases...
  32. doi request reprint Hepatitis C therapy with HCV NS5B polymerase inhibitors
    Vincent Soriano
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Expert Opin Pharmacother 14:1161-70. 2013
    ..It has good tolerability and a robust barrier to resistance. In contrast, non-nucleoside analogs have low to moderate antiviral potency, a low barrier to resistance and inhibit only HCV genotype 1...
  33. ncbi request reprint Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients
    Marina Nunez
    Department of Infectious Diseases Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Acquir Immune Defic Syndr 45:439-44. 2007
    ..Relapse after achieving virologic response to anti-hepatitis C virus (HCV) treatment considerably reduces sustained virologic response rates. It is unclear what the main predictors of relapse in HCV/HIV-coinfected patients are...
  34. ncbi request reprint Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin
    Vincent Soriano
    Hospital Carlos III, Madrid, Spain
    Antivir Ther 12:469-76. 2007
    ..Chronic hepatitis C therapy in HIV patients is often penalized by more frequent premature treatment discontinuations. It is unclear what the relative contribution of more adverse events and/or early virological failures are...
  35. ncbi request reprint Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos II, Madrid, Spain
    Antivir Ther 9:987-92. 2004
    ..However, the occurrence of liver complications (including hepatocellular carcinoma) and/or HCV relapses in coinfected patients when followed for long periods of time after HCV therapy is not well known...
  36. doi request reprint Different impact of IL28B polymorphisms on response to peginterferon-α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b
    Eugenia Vispo
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    J Clin Virol 55:58-61. 2012
    ..HCV subtype 1a has emerged as a predictor of poor response to triple hepatitis C therapy including boceprevir or telaprevir, which largely has been attributed to a lower resistance barrier in HCV-1a compared to -1b...
  37. ncbi request reprint Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients
    Jose Medrano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 49:1397-401. 2009
    ..However, episodes of HCV relapse occurred before week 12 in most cases, regardless of HIV status...
  38. ncbi request reprint Update on the treatment of chronic hepatitis C in HIV-infected patients
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Rev 9:99-113. 2007
    ..g. tenofovir, lamivudine, or emtricitabine). Didanosine should never be coadministered with ribavirin due to potential life-threatening complications...
  39. doi request reprint The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring
    Judit Morello
    Pharmacokinetic Unit, Hospital Carlos III, Madrid, Spain
    Ther Drug Monit 32:242-4. 2010
    ..Fasting triglycerides were also reduced in 2 of them. Plasma HIV-RNA remained undetectable in all patients, despite the observed decline in TPV trough concentrations...
  40. doi request reprint Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C
    Eugenia Vispo
    Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 26:419-24. 2010
    ..Extensive intraerythrocyte accumulation of RBV following boosted production of red blood cells by EPO could explain these findings...
  41. ncbi request reprint Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study
    Matilde Sanchez-Conde
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 23:1237-41. 2007
    ..Its efficacy does not seem to be compromised when ddI is administered with food. Therefore, this regimen merits further investigation in larger comparative trials...
  42. ncbi request reprint Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Madrid, 28029, Spain
    J Infect Dis 195:1181-3. 2007
    ..This information has important pathogenic implications and may influence therapeutic decisions...
  43. ncbi request reprint Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy
    Pablo Barreiro
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 4:361-71. 2003
    ....
  44. ncbi request reprint Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir
    Jose M Benito
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 18:709-15. 2013
    ..No head-to-head studies comparing TLV and BOC have been performed so far...
  45. ncbi request reprint Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C
    Marina Nunez
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 10:657-62. 2005
    ..The use of pegylated interferon (PEG-IFN) plus ribavirin (RBV) is currently the recommended treatment for chronic hepatitis C virus (HCV) infection. Coinfection with HIV is a negative predictor of response, for reasons not well understood...
  46. doi request reprint Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir
    Carmen de Mendoza
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 46:1782-5. 2008
    ..001), despite elevated and stable rates of tenofovir use. A reduction in the rate of coadministration of didanosine (from 41.6% of patients in 2004 to 0.8% of patients in 2006; P < .001) largely explained this observation...
  47. doi request reprint Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain
    Eva Poveda
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 17:571-5. 2012
    ..Herein, we report the current profile of HIV-HCV-coinfected patients at our institution in an attempt to predict the effect of DAAs...
  48. doi request reprint Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C
    Norma I Rallon
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 53:1291-5. 2011
    ..Anemia developed in 80% of patients with normal ITPA activity compared with 33% of those with reduced ITPA activity. In contrast, ITPA variants did not influence sustained virological response...
  49. ncbi request reprint Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy
    Eva Poveda
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 23:1078-82. 2007
    ....
  50. ncbi request reprint Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors
    Pablo Barreiro
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    Int J Antimicrob Agents 20:438-43. 2002
    ..The efficacy of rit-boosted PI combinations is greatly influenced by the extent of baseline PI resistance. Differences, not only in potency, but mainly in tolerance may favour the selection of one dual PI combination over others...
  51. doi request reprint Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy
    Paula Tuma
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 15:881-6. 2010
    ..Herein, we examine the incidence of cirrhosis, using TE assessment, in HIV-infected individuals with chronic hepatitis B or C receiving highly active antiretroviral therapy (HAART)...
  52. doi request reprint Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse
    Pablo Labarga
    Hospital Carlos III, Madrid, Spain
    AIDS 25:1131-3. 2011
    ..1 (2.7-90.9)], prior relapse [9.6 (1.5-62.4)] and ribavirin plasma trough concentrations at week 4 [4.9 (1.3-18.4)]. IL28B-CC only predicted response in prior nonresponders carrying HCV genotypes 1/4 [25.1 (1.9-337)]...
  53. ncbi request reprint Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients
    Belen Ramos
    Service of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Acquir Immune Defic Syndr 44:557-61. 2007
    ..Information available on the prevalence and distribution of distinct HBV variants in HIV-positive patients is scarce...
  54. ncbi request reprint Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 10:167-70. 2005
    ..HCV genotype 4 is spreading among European intravenous drug users, who are frequently coinfected with HIV. Information about treatment response in this subset of patients is scarce and conflicting results have been reported...
  55. ncbi request reprint Severe liver disease associated with prolonged exposure to antiretroviral drugs
    Ivana Maida
    Department of Infectious Diseases, Hospital Carlos III, Madrid Spain
    J Acquir Immune Defic Syndr 42:177-82. 2006
    ..However, the etiology of liver disease still remains unknown for a small subset of individuals...
  56. ncbi request reprint Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin
    Vincent Soriano
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 9:505-9. 2004
    ..Therefore, extending therapy (for 12 months in HCV genotypes 2/3 and perhaps for 18 months in HCV genotypes 1/4) might be warranted in HIV/HCV-coinfected patients showing EVR...
  57. ncbi request reprint Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity
    Matilde Sanchez-Conde
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 6:197-202. 2005
    ..Given that the toxicity might be dose-dependent, we explored prospectively whether lowering d4T doses might improve the safety profile of the drug without compromising its antiviral activity...
  58. doi request reprint Treatment failure with new hepatitis C drugs
    Vincent Soriano
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Expert Opin Pharmacother 13:313-23. 2012
    ..The addition of any of the two recently approved HCV protease inhibitors, boceprevir or telaprevir, to pegIFNα-RBV results in the cure for two-thirds of HCV genotype 1, interferon-naive patients...
  59. doi request reprint [Human immunodeficiency virus infection and viral hepatitis]
    Vicente Soriano
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Enferm Infecc Microbiol Clin 29:691-701. 2011
    ..However, interactions between these drugs and antiretroviral agents and the risk of selective resistance pose huge threats in this population...
  60. doi request reprint Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome
    Pilar Garcia-Gasco
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 61:699-704. 2008
    ..The rate, predictors and outcome following episodes of low-level viral rebound (LLVR) in HIV patients on highly active antiretroviral therapy (HAART) are unknown...
  61. ncbi request reprint Management of hepatitis B virus co-infection on and off antiretroviral therapy
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Curr HIV/AIDS Rep 5:86-93. 2008
    ..Hopefully, this success will translate into a halt of liver-related complications and death in the co-infected population...
  62. doi request reprint Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements
    Inmaculada Jimenez-Nacher
    Service of Pharmacy, Pharmacokinetics and Pharmacogenetics, Hospital Carlos III, Calle Sinesio Delgado 10, Madrid 28029, Spain
    J Antimicrob Chemother 62:816-22. 2008
    ..The choice of antiretroviral drugs has evolved over the last decade. Recognition of trends and determinants of changes may help to make predictions on prescription patterns...
  63. ncbi request reprint Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine
    Ana Barrios
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS 19:569-75. 2005
    ..The popularity of this combination, however, has been questioned due to concerns about pharmacokinetic interactions and increased risk of pancreatitis and hyperglycemia. Less information is available about other possible side effects...
  64. doi request reprint HIV protease inhibitors: recent clinical trials and recommendations on use
    José Vicente Fernández-Montero
    Hospital Carlos III, Department of Infectious Diseases, Madrid, Spain
    Expert Opin Pharmacother 10:1615-29. 2009
    ..PIs have evolved over the years to gain in potency, convenience, tolerability and genetic barrier to resistance...
  65. ncbi request reprint Raltegravir and etravirine are active against HIV type 1 group O
    Veronica Briz
    Department of Infectious Disease, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 25:225-7. 2009
    ..Therefore, individuals infected with HIV-1 group O might benefit from raltegravir and/or etravirine therapy...
  66. ncbi request reprint Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Antivir Ther 11:869-77. 2006
    ..Unfortunately, hepatitis C virus (HCV) therapy provides sustained virological response (SVR) to only 40% of coinfected patients. Little is known about the regression of hepatic fibrosis in treated patients...
  67. ncbi request reprint Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients
    Ana Lucía Rendon
    Pharmacy Service, Hospital Carlos III, Madrid, Spain
    J Acquir Immune Defic Syndr 39:401-5. 2005
    ..Therefore, early therapeutic drug monitoring might help to tailor RBV dosages, improving the efficacy and safety of anti-HCV treatment...
  68. ncbi request reprint Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients
    Maria José Nuñez
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 22:825-9. 2006
    ..All subjects with ARV-related toxicities had a favorable outcome, except one with prior HCVrelated end-stage liver disease, who died after experiencing hepatic decompensation following initiation of a protease inhibitor-based regimen...
  69. ncbi request reprint Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 42:1032-9. 2006
    ..The reasons for this faster liver disease progression are unclear, although higher plasma HCV RNA levels and distinct HCV genotype distribution in this population, compared with in HCV-monoinfected subjects, could play a role...
  70. doi request reprint Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients
    Eugenia Vispo
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 9:440-4. 2008
    ..All had received didanosine for long periods. Noncirrhotic portal hypertension associated with didanosine may appear in HIV patients without any liver disease or added to chronic hepatitis C...
  71. pmc Different viral rebound following discontinuation of antiretroviral therapy in cases of infection with viruses carrying L74V or thymidine-associated mutations
    Carmen de Mendoza
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Clin Microbiol 42:862-6. 2004
    ..01) in 12 subjects harboring thymidine-associated mutations; these mutations persisted in all instances. Thus, selection of an L74V mutation during didanosine therapy may compromise HIV replication in vivo...
  72. ncbi request reprint Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases
    Ivana Maida
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 23:801-4. 2007
    ..9% show persistently normal ALT levels. Nearly 25% of HIV-HCV-coinfected patients with persistently normal ALT show advanced liver fibrosis. Therefore, HCV-HIV-coinfected patients with normal ALT levels should be closely monitored...
  73. ncbi request reprint Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption
    Pablo Barreiro
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 41:897-900. 2005
    ..001). Distinct pharmacokinetics and resistance barriers may result in different performances for PIs and NNRTIs after treatment interruptions...
  74. ncbi request reprint Reproductive options for HIV-serodiscordant couples
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Rev 8:158-70. 2006
    ..This review discusses the pros and cons of reproductive options in HIV-infected persons and proposes a protocol for their counseling...
  75. ncbi request reprint Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides
    Pablo Barreiro
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    AIDS 16:245-9. 2002
    ..Combinations including non-nucleoside reverse transcriptase inhibitors (NNRTI) result in similar virological success, but data on immune reconstitution are scarce...
  76. ncbi request reprint Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Acquir Immune Defic Syndr 43:324-6. 2006
    ..Serodiscordant couples attaining natural pregnancy are exposed to a negligible risk of sexual transmission of HIV when the infected partner presents with complete suppression of plasma viremia while receiving HAART...
  77. ncbi request reprint Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    J Antimicrob Chemother 57:806-9. 2006
    ..Interference between the pathways leading to the intracellular activation of didanosine and tenofovir, and their blocking of the purine nucleoside phosphorylase, seems to explain this phenomenon...
  78. ncbi request reprint Replacement of protease inhibitors by nevirapine or efavirenz in simplification and rescue interventions: which works better?
    Pablo Barreiro
    Service of Infectious Diseases, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 4:244-7. 2003
    ..Both drugs were generally well tolerated, although specific toxicities could make one drug more suitable than the other for certain patients...
  79. ncbi request reprint Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine
    Jose Miguel Benito
    Department of Infectious Diseases, Hospital Carlos III, Madrid 28029, Spain
    AIDS Res Hum Retroviruses 22:734-43. 2006
    ..Nef-specific CD8+ responses might contribute to a better virological control of HIV replication following treatment interruptions in HIV-infected individuals and might be boosted by the immunomodulatory effect of HU...
  80. ncbi request reprint Combinations of nucleoside/nucleotide analogues for HIV therapy
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Rev 6:234-43. 2004
    ..Interferences between the pathways involved into the intracellular activation of some nucleoside/nucleotide analogues may help to understand why certain drug combinations should be avoided...
  81. ncbi request reprint [Therapeutic strategies in HIV infection]
    Pablo Barreiro
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Madrid, Espana
    Med Clin (Barc) 124:661-7. 2005
  82. ncbi request reprint Atazanavir: the advent of a new generation of more convenient protease inhibitors
    Pablo Barreiro
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 6:50-61. 2005
    ..Recent clinical studies support the assertion that atazanavir may display excellent behavior as part of first-line regimens in rescue interventions or in simplification strategies...
  83. ncbi request reprint SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals
    Marina Nunez
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:186-94. 2002
    ..A randomized, open-label, pilot study was undertaken to explore the antiviral activity and tolerability of two nonnucleoside reverse transcriptase inhibitors (NNRTIs), nevirapine (NVP) and efavirenz (EFV)...
  84. ncbi request reprint Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir
    Luisa Valer
    Service of Infectious Diseases and Service of Pharmacy, Instituto de Salud Carlos III, Madrid, Spain
    AIDS 16:1964-6. 2002
  85. ncbi request reprint Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families
    Carmen de Mendoza
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    HIV Clin Trials 3:304-9. 2002
    ..It has shown greater potency than the former PIs in phase II/III trials, either in naive or in PI-experienced patients being naive for nonnucleoside reverse transcriptase inhibitors (NNRTIs)...
  86. ncbi request reprint Avascular necrosis in HIV-infected patients receiving antiretroviral treatment: study of seven cases
    Ma Eulalia Valencia
    Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 4:132-6. 2003
    ..We analyzed clinical, radiological, scintigraphical, epidemiological, and immunological data in a group of HIV-infected patients with osteonecrosis...
  87. ncbi request reprint Enfuvirtide is active against HIV type 1 group O
    Eva Poveda
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    AIDS Res Hum Retroviruses 21:583-5. 2005
    ..After initiating treatment with ENF, a significant decline in plasma HIV-RNA and CD4 gain was noticed in one patient. Therefore, individuals with HIV-1 group O strains might benefit from ENF therapy...
  88. ncbi request reprint Emerging drugs for hepatitis C
    Vincent Soriano
    Hospital Carlos III, Department of Infectious Diseases, Calle Sinesio Delgado 10, Madrid 28029, Spain
    Expert Opin Emerg Drugs 13:1-19. 2008
    ....
  89. ncbi request reprint Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome
    Ivana Maida
    Department of Infectious Diseases, Hospital Carlos III, Madrid Spain
    Antivir Ther 13:103-7. 2008
    ..Herein, we examine the clinical outcome following ddl removal...
  90. doi request reprint Viral hepatitis and HIV co-infection
    Vincent Soriano
    Infectious Diseases Department, Hospital Carlos III, Madrid, Spain
    Antiviral Res 85:303-15. 2010
    ..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010...
  91. ncbi request reprint Management of chronic hepatitis B and C in HIV-coinfected patients
    Vincent Soriano
    Department of Infectious Diseases, Hospital Carlos III, Calle Sinesio Delgado 10, 28029 Madrid, Spain
    J Antimicrob Chemother 57:815-8. 2006
    ..Several guidelines have recently been released in response to this demand. In this article, we discuss the most critical issues highlighted in these documents...
  92. ncbi request reprint Simplification of antiretroviral treatment--how to sustain success, reduce toxicity and ensure adherence avoiding PI use
    Pablo Barreiro
    Service of Infectious Diseases, Hospital Carlos III, Instituto de Salud Carlos III, Madrid, Spain
    AIDS Rev 4:233-41. 2002
    ..Patients taking methadone may require dosage increases with switches to either NVP or EFV...
  93. ncbi request reprint Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin
    Vincent Soriano
    AIDS 20:2225-7. 2006
  94. ncbi request reprint Nucleoside/nucleotide backbones for the treatment of HIV infection
    Pablo Barreiro
    Service of Infectious Diseases and Service of Pharmacy, Hospital Carlos III, Madrid 28029, Spain
    Curr Opin Investig Drugs 6:812-22. 2005
    ..Moreover, the knowledge of plasma and intracellular interactions between different NAs is important for choosing appropriate combinations and optimal doses in order to optimize antiviral efficacy and minimize toxicities...
  95. ncbi request reprint Pharmacogenetics in HIV therapy
    Sonia Rodriguez-Novoa
    Pharmacokinetic Unit, Hospital Carlos III, Madrid, Spain
    AIDS Rev 7:103-12. 2005
    ..Herein, we review the genetic polymorphisms known to be associated with altered pharmacokinetics of antiretrovirals, which may influence the efficacy and toxicity of these drugs...
  96. ncbi request reprint [Reproductive advice in HIV-discordant couples]
    Pablo Labarga
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Sinesio Delgado 10, 28029 Madrid, Spain
    Med Clin (Barc) 129:140-8. 2007
  97. ncbi request reprint Outbreak of syphilis, but not of acute hepatitis C, among HIV-infected homosexual men in Madrid
    Andres Ruiz-Sancho
    Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    HIV Clin Trials 8:98-101. 2007
    ..Clustered cases of acute hepatitis C virus (HCV) infection, frequently accompanied by sexually transmitted diseases, have recently been reported among men who have sex with men (MSM) in several European cities...
  98. ncbi request reprint Antiretroviral drugs and liver injury
    Vincent Soriano
    AIDS 22:1-13. 2008
  99. ncbi request reprint Outbreaks of acute hepatitis C among HIV+ homosexual men in Europe
    Pablo Barreiro
    AIDS Rev 8:110-1. 2006
  100. ncbi request reprint Tolerance of didanosine as enteric-coated capsules versus buffered tablets
    Pablo Barreiro
    Service of Infectious Diseases Hospital Carlos III Madrid, Spain
    AIDS Patient Care STDS 18:329-31. 2004
  101. ncbi request reprint Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea
    Mariola Lopez
    Service of Infectious Diseases, Hospital Carlos III Madrid, Spain
    AIDS 18:1251-61. 2004
    ..The role of hydroxyurea (HU) in the treatment of HIV infection remains controversial. HU potentiates didanosine (ddI) antiviral activity and might exert immunomodulatory effects...